Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
S.G. Deeks, T. Wrin, T. Liegler, R. Hoh, M. Hayden, J. Barbour, et al.
Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
N Engl J Med, 344 (2001), pp. 472-480
[2.]
A.S. Perelson, A.U. Neumann, M. Markowitz, J.M. Leonard, D.D. Ho.
HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span and viral generation time.
Science, 271 (1996), pp. 1582-1586
[3.]
D.D. Ho, A.U. Neumann, A.S. Perelson, W. Chen, J.M. Leonard, M. Markowitz.
Rapid turnover of plasma virions and CD4+lymphocytes in HIV-1 infection.
Nature, 373 (1995), pp. 123-126
[4.]
D. Havlir.
Structured intermittent treatment for HIV disease. Necessary concession or premature compromise?.
Proc Natl Acad Sci, 99 (2002), pp. 4-6
[5.]
British HIV Association (BHIVA) Guidelines for the Treatment of HIV-Infected Adults with Antiretroviral Therapy. July 2001. Disponible en; http://wwwaidsmapcom/about/bhiva/guidelinespdf2001
[6.]
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents (NIH). February 2002. Disponible en: http://hivatisorg/trtgdlnshtml#Adult2002
[7.]
H. Knobel, A. Carmona, S. Grau, J. Pedro-Botet, A. Diez.
Adherence and effectiveness of highly active antiretroviral therapy.
Arch Intern Med, 158 (1998), pp. 1953
[8.]
D. Finzi, J. Blankson, J.D. Siliciano, J.B. Margolick, K. Chadwick, T. Pierson, et al.
Latent infection of CD4+T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy.
Nat Med, 5 (1999), pp. 512-517
[9.]
E. Martinez, A. Mocroft, M. Garcia-Viejo, J. Perez-Cuevas, J. Blanco, J. Mallolas, et al.
A prospective cohort study on the risk for lipodystrophy in HIV-1 infected patients treated with protease inhibitor-containing regimens.
Lancet, 357 (2001), pp. 592-598
[10.]
R.S. Hogg, B. YIP, K. Chan, E. Wood, K.J.P. Craib, M.V. O’Shaughnessy, et al.
Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
JAMA, 286 (2001), pp. 2568-2577
[11.]
A.N. Phillips, S. Staszewki, R. Weber, O. Kirk, P. Francioli, V. Miller, et al.
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.
JAMA, 286 (2001), pp. 2560-2567
[12.]
L. Ruiz, G. Carcelain, J. Martinez-Picado, S.D. Frost, S. Marcia, R. Paredes, et al.
HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection.
AIDS, 15 (2001), pp. F19-F27
[13.]
F. García, M. Plana, G.M. Ortiz, S. Bonhoeffer, A. Soriano, C. Vidal, et al.
The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection.
AIDS, 15 (2001), pp. F29-F40
[14.]
M. Dybul, T.W. Chun, C. Yoder, B. Hidalgo, M. Belson, K. Hertogs, et al.
Short-cycle structured treatment of chronic HIV infection with higly active antiretroviral therapy: Effects on virologic, immunologic and toxicity parameters.
Proc Natl Acad Sci, 98 (2001), pp. 15161-15166
[15.]
G. Carcelain, R. Tubiana, A. Samri, V. Calvez, C. Delaugerre, H. Agut, et al.
Transient mobilization of human immunodeficiency virus (HIV)-specific CD4 T-helper cells fails to control virus rebounds during intermittent antiretroviral therapy in chronic HIV type 1 infection.
J Virol, 75 (2001), pp. 234-241
[16.]
Fagard C, Lebraz M, Gunthard H, Tortajada C, García F,et al. SSITT: A prospective trial of strategic treatment interruptions in 128 patients. Abstract 357. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, 4th-8th, 2001.
[17.]
G.M. Ortiz, M. Wellons, J. Brancato, H. Vo, R. Zinn, D. Clarkson, et al.
Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.
Proc Natl Acad Sci, 98 (2001), pp. 13288-13293
[18.]
S.D.W. Frost, J. Martinez-Picado, L. Ruiz, B. Clotet, A.J. Brown.
Viral dynamics during structured treatment interruptions of chronic human immunodeficiency virus type 1 infection.
J Virol, 76 (2002), pp. 968-979
[19.]
García F, Plana M, Mestre G,et al. Immunologic and virologic factors at baseline may predict response to structured therapy interruption in early stage chronic HIV-1 infection. AIDS 2002. En prensa.
[20.]
F. García, M. Plana, C. Vidal, A. Cruceta, W.A. O’Brien, G. Pantaleo, et al.
Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
AIDS, 13 (1999), pp. F79-F86
[21.]
A.U. Neumann, R. Tubiana, V. Calvez, C. Robert, T.S. Li, H. Agut, et al.
HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiation of treatment.
AIDS, 13 (1999), pp. 677-683
[22.]
E.S. Rosenberg, M. Altfeld, S. Poon, M. Phillips, B. Wilkes, R. Eldridge, et al.
Immune control of HIV-1 after early treatment of acute infection.
Nature, 407 (2000), pp. 523-526
[23.]
Moser J, Gibbs J, Jensen P, Lukacher A. CD94-NKG2A receptors regulate antiviral CD8+T cell responses. Nat Immunol 2002; Published online: 22 January 2002, DOI:10.1038/ni757.
[24.]
M. Gavin, S. Clarke, E. Negrou, A. Gallegos, A. Rudensky.
Homeostasis and anergy of CD4?CD25+suppressor T cells in vivo.
Nat Immunol, 3 (2002), pp. 33-41
[25.]
Garcia F, Plana M, Brunet M, et al. Effect of Associating an Immunosuppressive Therapy (Mycophenolate Mofetil: MMF) + HAART during STI and Holding the MMF Drug after Definitive Interruption of HAART on Viral Replication. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, USA, February 24-28, 2002.
[26.]
Plana M, García F, Ortiz GM. Influence of hydroxyurea (HU) associated with HAART and maintained during periods off antiretroviral therapy in STI on the HIV-1-specific immune responses. Abstract 356. Chicago, 8th Conference on Retroviruses and Opportunistic Infections, 4th-8th February, 2001
[27.]
G.P. Rizzardi, M. Vaccarezza, B. Capiluppi, G. Tambussi, A. Lazzarin, G. Pantaleo.
Cyclosporin A in combination with HAART in primary HIV-1 infection.
J Biol Regul Homeost Agents, 14 (2000), pp. 79-81
[28.]
A. Chapuis, P. Rizzardi, C. D’Agostini, A. Attinger, C. Knabenhans, S. Fleury, et al.
Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo.
Nat Med, 6 (2000), pp. 762-768
[29.]
Tremblay C, Hicks J, Sutton L. HIV evolution during repeated supervised treatment interruptions following early antiretroviral treatment of acute infection. Abstract 19. 5th International Workshop on HIV Drug Resistance & Treatment Strategies; June 4-8, 2001; Scottsdale,Arizona.
[30.]
Martinez-Picado J, Morales-Lopetegui K, Wrin T, et al. Selection of the M184V mutation during repetitive cycles of structured antiretroviral treatment interruptions. Abstract 36. 5th International Workshop on HIV Drug Resistance & Treatment Strategies; June 4-8, 2001; Scottsdale, Arizona.
[31.]
B. Ramratnam, J. Mittler, L. Zhang, D. Boden, A. Hurley, F. Fang, et al.
The dacay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy.
Nat Med, 6 (2000), pp. 82-85
[32.]
J.C. Lopez, J.M. Miró, J.M. Peña, D. Podzamczer, J.C. Alberdi, E. Martinez, et al.
A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection.
N Engl J Med, 344 (2001), pp. 159-167
[33.]
M. Plana, F. Garcia, T. Gallart, J.M. Miro, J.M. Gatell.
Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study.
Lancet, 352 (1998), pp. 1194-1195
[34.]
Lejeune M, Plana M, Martínez C, García F, Maleno MJ, Miró JM, et al. Células dendríticas derivadas de monocitos como posible adyuvante celular para una vacuna terapéutica en pacientes infectados por el VIH. Estudios preliminares in vitro. XVI Congreso de la Sociedad Española de Inmunología. Sevilla 23-26, mayo 2000.
[35.]
Lejeune M, Plana M, Martínez C, García F, Maleno MJ, Miró JM, et al. Generation of monocyte-derived dendritic cells (MD-DC) in clinical GMP conditions and their ability to activate CD4 and CD8 T cells to HIV antigens in early HIV +individuals receiving HAART. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, February 24-28, 2002.
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
